NCT03982992 - Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab | Biotech Hunter

Timeline

Start Date

June 1, 2019

Primary Completion Date

May 31, 2021

Study Completion Date

November 30, 2021

Conditions

B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell TransplantationB-Cell Acute Lymphoblastic LeukemiaAcute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia in RemissionAcute Lymphoblastic Leukemia, Adult

Interventions

DRUG

Blinatumomab in combination with donor lymphocyte infusion

Continuous blinatumomab infusion in combination with allogeneic donor lymphocyte infusion

Trial Locations (1)

81377

Klinikum der Universität München, Munich